These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38158168)

  • 21. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse events following third dose of mRNA COVID-19 vaccination among nursing home residents who received the primary series.
    Bardenheier BH; White EM; Blackman C; Gravenstein S; Gutman R; Sarkar IN; Feifer RA; McConeghy K; Nanda A; Duprey M; Mor V
    J Am Geriatr Soc; 2022 Jun; 70(6):1642-1647. PubMed ID: 35460263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
    Anastassopoulou C; Boufidou F; Hatziantoniou S; Vasileiou K; Spanakis N; Tsakris A
    Vaccine; 2023 Nov; 41(48):7176-7182. PubMed ID: 37891048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.
    Lane S; Yeomans A; Shakir S
    BMJ Open; 2022 May; 12(5):e059223. PubMed ID: 35613761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database.
    Thai-Van H; Valnet-Rabier MB; Anciaux M; Lambert A; Maurier A; Cottin J; Pietri T; Destère A; Damin-Pernik M; Perrouin F; Bagheri H
    JMIR Public Health Surveill; 2023 Jul; 9():e45263. PubMed ID: 37071555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea.
    Kim HJ; Kim MH; Park SJ; Choi MG; Chun EM
    J Allergy Clin Immunol; 2024 Jun; 153(6):1711-1720. PubMed ID: 38520423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe Multisystem Inflammatory Symptoms in 2 Adults after Short Interval between COVID-19 and Subsequent Vaccination.
    Jenny-Avital ER; Howe RA
    Emerg Infect Dis; 2022 May; 28(5):1017-1020. PubMed ID: 35320702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination.
    Formeister EJ; Wu MJ; Chari DA; Meek R; Rauch SD; Remenschneider AK; Quesnel AM; de Venecia R; Lee DJ; Chien W; Stewart CM; Galaiya D; Kozin ED; Sun DQ
    JAMA Otolaryngol Head Neck Surg; 2022 Apr; 148(4):307-315. PubMed ID: 35201274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System.
    Pawlowski C; Rincón-Hekking J; Awasthi S; Pandey V; Lenehan P; Venkatakrishnan AJ; Bade S; O'Horo JC; Virk A; Swift MD; Williams AW; Gores GJ; Badley AD; Halamka J; Soundararajan V
    J Stroke Cerebrovasc Dis; 2021 Oct; 30(10):105923. PubMed ID: 34627592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial fibrillation after vaccination for COVID-19: analysis of the vaccine adverse event reporting system.
    Kumar A; Shariff M; Bhat V; DeSimone C; Deshmukh A
    J Interv Card Electrophysiol; 2022 Oct; 65(1):1-2. PubMed ID: 35674855
    [No Abstract]   [Full Text] [Related]  

  • 33. Trends in reporting embolic and thrombotic events after COVID-19 vaccination: A retrospective, pharmacovigilance study.
    Kan Y; Asada M; Uesawa Y
    PLoS One; 2022; 17(8):e0269268. PubMed ID: 35913955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults.
    Cappelletti-Montano B; Demuru G; Laconi E; Musio M
    Front Public Health; 2023; 11():1145645. PubMed ID: 37377545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low Rates of Urologic Side Effects Following Coronavirus Disease Vaccination: An Analysis of the Food and Drug Administration Vaccine Adverse Event Reporting System.
    Zhao H; Souders C; Carmel M; Anger JT
    Urology; 2021 Jul; 153():11-13. PubMed ID: 33864857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System.
    Moro PL; Olson CK; Zhang B; Marquez P; Strid P
    Obstet Gynecol; 2022 Sep; 140(3):421-427. PubMed ID: 35926203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years.
    Hause AM; Shay DK; Klein NP; Abara WE; Baggs J; Cortese MM; Fireman B; Gee J; Glanz JM; Goddard K; Hanson KE; Hugueley B; Kenigsberg T; Kharbanda EO; Lewin B; Lewis N; Marquez P; Myers T; Naleway A; Nelson JC; Su JR; Thompson D; Olubajo B; Oster ME; Weintraub ES; Williams JTB; Yousaf AR; Zerbo O; Zhang B; Shimabukuro TT
    Pediatrics; 2022 Aug; 150(2):. PubMed ID: 35581698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
    Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
    JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
    Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
    Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination.
    Sprow G; Afarideh M; Dan J; Feng R; Keyes E; Grinnell M; Concha J; Werth VP
    Front Immunol; 2022; 13():899526. PubMed ID: 35693768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.